Skip to content

GH-IGF-1 axis changes and rhGH therapy in obese children and Obesity-related cardiovascular and metabolic complications

GH-IGF-1 axis changes and rhGH therapy in obese children and Obesity-related cardiovascular and metabolic complications

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042793
Enrollment
Unknown
Registered
2021-01-28
Start date
2021-01-26
Completion date
Unknown
Last updated
2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesity

Interventions

experimental group:rhGH theatment

Sponsors

The Second Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 18 Years

Inclusion criteria

Inclusion criteria: All subjects were obese (Body mass index (BMI)> 95th percentile for the age and sex), but otherwise healthy.

Exclusion criteria

Exclusion criteria: 1) Secondary obesity; 2) Positive hepatitis B surface antigen, positive hepatitis C antibodies or other liver disease such as Wilson's disease or autoimmune hepatitis etc; 3) Diabetes, hypothalamus-pituitary diseases or other disease condition known to affect the GH axis; 4) Children who ever have had alcohol intake, smoked or used drugs which may influence liver function, glucose, lipid metabolism or weight within the 3 months prior to study; 5) Serious infection, systemic disease, and other chronic wasting illnesses; 6) Short stature or growth velocity is less than 5 cm/year.

Design outcomes

Primary

MeasureTime frame
IGF-1;

Countries

China

Contacts

Public ContactShuang Liang

The Second Hospital of Shandong University

liangshuang3508@163.com+86 17660082768

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026